Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Investigational Drug Update for January 22

1/21/2019

 
According to Forbes “While the FDA is continuing to carry out reviews funded by fiscal year (FY) 2018 Prescription Drug User Fee Act user fees, including the review and approval of new drugs and biologics funded by carryover user fee balances, the agency is not accepting FY 2019 user fees until funding appropriations have been authorized, i.e., the political impasse has been resolved. Consequently, the FDA has suspended reviews of existing Investigational New Drug (IND) and Biologics License Application (BLA) applications not covered by user fees and is not reviewing applications for new drugs and biologics submitted during the shutdown period, except for emergency INDs and BLAs. The FDA is also not reviewing medical device applications submitted during the lapse period. And, the FDA is curtailing work on regulatory guidance documents pertaining to medical devices, drugs, and biologics.”

FDA Actions in spite of the shutdown… 

The FDA has accepted two NDAs from Pfizer on 1/14/19 for tafamidis. Tafamidis meglumine was granted a priority review with a July 2019 PDUFA date and the free acid of tafamidis will receive a standard review with a November 2019 PDUFA date. Tafamidis meglumine requires four 20 mg capsules for a dose, while 61 mg of the free acid will be available as a single capsule. 

The FDA granted serlopitant Breakthrough Therapy status in January 2019. 

The FDA Bone, Reproductive and Urologic Drugs Advisory Committee voted 18-1 to recommend approval of romosozumab on 1/17/2019, but also recommended a boxed warning for cardiovascular safety.

The FDA rejected sacituzumab govitecan on 1/17/2019 due to problems with manufacturing the drug. 

Eisai and Purdue Pharma submitted an NDA for lemborexant in January 2019.

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee had a split decision (8-8) on sotagliflozin on whether to recommend approval of the drug as an add-on to insulin therapy in patients with type 1 diabetes on 1/17/2019. Some members of the committee expressed concern regarding the increased risk for diabetic ketoacidosis with the drug. 

Research Updates

In a 52-week open label extension of a Phase III idalopirdine trial, no beneficial effects were seen. Idalopirdine was safe and well tolerated when added to donepezil, and memantine.

In a 2-year, 86 patient, Phase II, open label, single arm, Chinese trial, treatment with zanubrutinib resulted in an overall response rate of 83.5% with a progression free survival in 82% of patients with Mantle Cell Lymphoma.

An evaluation of data from the STRATOS 1 and 2 trials suggested there was no risk of severe hypersensitivity or anaphylactic reactions with tralokinumab.

In a 138-patient trial, treatment with udenafil decreases postmicturition dribbling in healthy men with a mean age of 57.6 years.

Phase III data identified an increased risk for stroke that caused Merck to discontinue development of odanacatib.

In a 6-month, 38 patient Phase I/II trial, treatment with voxelotor increased hemoglobin and reduced hemolysis in patients with sickle cell disease.


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.